Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States

Centers for Disease Control and Prevention. (2020). Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States. (Added 12/30/2020.) U.S. Department of Health and Human Services.
This page offers clinical considerations for the Pfizer-BioNTech and Moderna COVID-19 vaccines related to: administration; interchangeability with other COVID-19 vaccine products; coadministration with other vaccines; booster doses, vaccination of those with SARS-CoV-2 infection or exposure; vaccination of persons with underlying medical conditions, immunocompromised persons, pregnant or lactating people, and adolescents; patient counseling; contraindications and precautions; reporting of vaccine adverse events; and interpretation of SARS-CoV-2 test results in vaccinated persons. It includes a table to inform the triage of persons presenting for vaccination.
Rate:
Favorite:
You must Login to add a comment
  • This item doesn't have any comments

Enter your email address to receive important announcements and updates through the ASPR TRACIE Listserv.